Male late-onset hypogonadism: pathogenesis, diagnosis and treatment

被引:70
作者
Huhtaniemi, Ilpo [1 ]
Forti, Gianni [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England
[2] Univ Florence, Endocrinol Unit, Dept Clin Physiopathol, I-50139 Florence, Italy
关键词
PLACEBO-CONTROLLED TRIALS; BIOAVAILABLE TESTOSTERONE LEVELS; SYMPTOMATIC ANDROGEN DEFICIENCY; BONE-MINERAL DENSITY; MIDDLE-AGED MEN; OLDER MEN; SERUM TESTOSTERONE; ELDERLY-MEN; AGING MEN; TRANSDERMAL TESTOSTERONE;
D O I
10.1038/nrurol.2011.47
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Some aging men develop a condition of suppressed serum testosterone levels, which is associated with diffuse sexual, physical and psychological symptoms. Several terms are used for this syndrome, but late-onset hypogonadism (LOH) is preferred. The diagnosis of LOH is often uncertain because symptoms (occurring in 20-40% of men) and low circulating testosterone (found in 20% of men > 70 years of age) seldom occur together. The strict diagnostic criteria for LOH include reproducibly low serum testosterone levels and sexual symptoms, including erectile dysfunction and reduced frequency of sexual thoughts and morning erections. Using these diagnostic criteria, only 2% of 40-80-year-old men have LOH. Obesity and impaired general health (including diabetes mellitus, cardiovascular and chronic obstructive pulmonary disease, and frailty) are more common reasons for low testosterone than advanced age per se. It seems logical, therefore, to begin by treating these conditions before testosterone replacement therapy is initiated. Even then, testosterone should only be used if there are no contraindications, such as unstable cardiac disease, serious prostate symptoms and high hemoglobin level. The long-term benefit of testosterone replacement therapy is uncertain, and the experimental nature of the treatment, and its associated risks, must be fully explained to the patient before treatment begins.
引用
收藏
页码:335 / 344
页数:10
相关论文
共 61 条
[1]   Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone [J].
Amory, JK ;
Watts, NB ;
Easley, KA ;
Sutton, PR ;
Anawalt, BD ;
Matsumoto, AM ;
Bremner, WJ ;
Tenover, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :503-510
[2]   Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study [J].
Araujo, AB ;
O'Donnell, AB ;
Brambilla, DJ ;
Simpson, WB ;
Longcope, C ;
Matsumoto, AM ;
McKinlay, JB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) :5920-5926
[3]   Prevalence of symptomatic androgen deficiency in men [J].
Araujo, Andre B. ;
Esche, Gretchen R. ;
Kupelian, Varant ;
O'Donnell, Amy B. ;
Travison, Thomas G. ;
Williams, Rachel E. ;
Clark, Richard V. ;
McKinlay, John B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) :4241-4247
[4]   Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis [J].
Bachman, Eric ;
Feng, Rui ;
Travison, Thomas ;
Li, Michelle ;
Olbina, Gordana ;
Ostland, Vaughn ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Basaria, Shehzad ;
Ganz, Tomas ;
Westerman, Mark ;
Bhasin, Shalender .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (10) :4743-4747
[5]   Adverse Events Associated with Testosterone Administration [J].
Basaria, Shehzad ;
Coviello, Andrea D. ;
Travison, Thomas G. ;
Storer, Thomas W. ;
Farwell, Wildon R. ;
Jette, Alan M. ;
Eder, Richard ;
Tennstedt, Sharon ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Choong, Karen ;
Lakshman, Kishore M. ;
Mazer, Norman A. ;
Miciek, Renee ;
Krasnoff, Joanne ;
Elmi, Ayan ;
Knapp, Philip E. ;
Brooks, Brad ;
Appleman, Erica ;
Aggarwal, Sheetal ;
Bhasin, Geeta ;
Hede-Brierley, Leif ;
Bhatia, Ashmeet ;
Collins, Lauren ;
LeBrasseur, Nathan ;
Fiore, Louis D. ;
Bhasin, Shalender .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02) :109-122
[6]   Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years [J].
Behre, HM ;
von Eckardstein, S ;
Kliesch, S ;
Nieschlag, E .
CLINICAL ENDOCRINOLOGY, 1999, 50 (05) :629-635
[7]   Biochemical endocrinology of the hypogonadal male [J].
Belchetz, Paul E. ;
Barth, Julian H. ;
Kaufman, Jean-Marc .
ANNALS OF CLINICAL BIOCHEMISTRY, 2010, 47 :503-515
[8]  
Bhasin S, 2003, J GERONTOL A-BIOL, V58, P1002
[9]  
Bhasin S, 2003, J ANDROL, V24, P299
[10]   Testosterone dose-response relationships in healthy young men [J].
Bhasin, S ;
Woodhouse, L ;
Casaburi, R ;
Singh, AB ;
Bhasin, D ;
Berman, N ;
Chen, XH ;
Yarasheski, KE ;
Magliano, L ;
Dzekov, C ;
Dzekov, J ;
Bross, R ;
Phillips, J ;
Sinha-Hikim, I ;
Shen, RQ ;
Storer, TW .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06) :E1172-E1181